Results 191 to 200 of about 252,158 (241)

Specific psychiatric symptoms during cannabis use and their relation to psychotic disorders. [PDF]

Indian J Psychiatry
Buciuta A, Coman HG, Nemeș B, Oroian R, Lesinschi A, Caranfil N, Vică ML, Matei HV.   +7 more
europepmc   +1 more source

Bipolar Disorder as a Long‐Term Risk Factor for Parkinson's Disease: A Nationwide Case–Control Study

Movement Disorders, EarlyView.
Abstract Background Previous studies suggest an association between bipolar disorder (BD) and an increased risk of Parkinson's disease (PD), but the long‐term temporal relationship remains unclear. Particularly, it is unclear whether the risk of PD is influenced by the duration since BD diagnosis.
Elina Jaakkola, Marjaana Koponen, Valtteri Kaasinen, Jarmo Hietala, Sirpa Hartikainen, Anna‐Maija Tolppanen   +5 more
wiley   +1 more source

Transdiagnostic Patterns of Grip Strength in Schizophrenia, Current Depression, and Remitted Depression.

JAMA Psychiatry
von Känel S, Pavlidou A, Nadesalingam N, Chapellier V, Nuoffer MG, Maderthaner L, Kyrou A, Malifatouratzis A, Wüthrich F, Lefebvre S, Pokorny V, Anderson Z, Shankman SA, Mittal VA, Walther S.   +14 more
europepmc   +1 more source

Replicated evidence for an accelerated rate of whole-body aging in schizophrenia. [PDF]

Psychol Med
Whitman ET, Passiatore R, Knodt AR, Pergola G, Antonucci LA, Bertolino A, Blasi G, D'Ambrosio E, Elliott ML, Kikidis GC, Lella A, Lupo A, Raio A, Rampino A, Sambuco N, Selvaggi P, Weinberger DR, Moffitt TE, Caspi A, Hariri AR.   +19 more
europepmc   +1 more source

Társadalmi szerkezet - műveltség - deviancia : gyűjtemény a TIT Szegedi XV. Művelődéselméleti Nyári Egyetemének előadásaiból [PDF]

, 1986

core  

Accelerating Medicines Partnership® Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research

Movement Disorders, EarlyView.
Abstract Background Recent advances in proteomic profiling have enabled its use as a powerful approach in elucidating molecular mechanisms underlying Parkinson's disease, enabling the identification of disease‐associated protein alterations and candidate biomarkers for diagnosis, progression, and therapeutic response.
Victoria J. Dardov, Aparna Vasanthakumar, Ameya Kulkarni, Niveda Sundararaman, Rakhi Pandey, Preeti Bais, Jennifer E. Van, Maria Quinton, Barry Landin, David Vismer, Bradford Casey, Matt Bookman, Willy Nojopranoto, Erin Teeple, Can Kayatekin, Rajaraman Krishnan, Richard Hargreaves, Guhan Nagappan, S. Pablo Sardi, Sri Ramulu Pullagura, Christine Swanson‐Fischer, Accelerating Medicines Partnership Parkinson's Disease (AMP PD) Proteomics Working Group   +21 more
wiley   +1 more source

Expression of Concern: Schizophrenia as a Network Disease: Disruption of Emergent Brain Function in Patients with Auditory Hallucinations. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain

Movement Disorders, EarlyView.
Abstract Background Serotonergic and dopaminergic pathways are implicated in Parkinson's disease psychosis (PDP), but preliminary evidence also implicates the endocannabinoid system (ECS). Objectives We examined the association of gray matter volume loss in PDP patients with brain expression of the genes coding for CB1 (cannabinoid type 1) and CB2 ...
Sara Pisani, František Váša, Latha Velayudhan, Sagnik Bhattacharyya   +3 more
wiley   +1 more source

Exploring the roots of schizophrenia: Current research and future directions (Review). [PDF]

Exp Ther Med
Lv S, Luo C.
europepmc   +1 more source